Published November 24, 2025 1 min read

# GLP-1 trial in Alzheimer’s comes up empty (and why that is not the whole story)

## The short version

Oral semaglutide did not slow early symptomatic Alzheimer's in two large trials of about 3,800 people. That miss outweighs hopeful headlines for treating disease you already have. It does not answer whether starting a GLP-1 drug earlier could still help prevent dementia.

By the OutliveAPOE4 editorial team. [How we research & source](/methodology).

On November 24, 2025, Novo Nordisk reported topline results from EVOKE and EVOKE+, two phase 3 trials of oral semaglutide, a GLP-1 medicine (glucagon-like peptide-1, a gut hormone that helps regulate appetite and blood sugar), in people who already had early symptomatic Alzheimer’s. Across roughly **3,800** participants over 2 years, the drug did **not** slow disease progression on the primary cognitive endpoint, the Clinical Dementia Rating-Sum of Boxes (CDR-SB), an 18-point cognition-and-function scale on which higher scores mean greater impairment. The secondary measures did not rescue it. It did move some Alzheimer’s biomarkers, but that did not translate into a clinical benefit.

The deeper [GLP-1 evidence review](/topics/glp-1-drugs-and-the-brain) separates randomized outcomes from observational signals. For the underlying insulin-resistance mechanism, and measures that are actionable now, continue to [metabolic health and the APOE4 brain](/topics/metabolic-health-insulin-resistance-apoe4).

The teaching point matters more than the result. Treating established disease is a different question from preventing it years earlier. So a negative treatment trial does not settle the prevention question, and it should not be read as one.

It also does not validate the hopeful headlines. The large observational signal that “GLP-1 drugs lower dementia risk” comes from people who choose or qualify for these drugs, a setup that is prone to bias and routinely overstates effects. A clean negative trial here is a useful reminder to weight a randomized result over an observational one.

Dedicated prevention trials are still running, and the oral semaglutide tested here is not identical to the injectable versions or to tirzepatide, so this is one drug in one setting, not the whole class.

Full context in our deep dive on [GLP-1 drugs and the brain](/topics/glp-1-drugs-and-the-brain). Primary source: Novo Nordisk’s topline announcement, 2025.

## Source & references

1.  [Alzheimer Europe / Novo Nordisk, 2025](https://www.alzheimer-europe.org/news/results-evoke-and-evoke-trials-show-no-effect-oral-semaglutide-ad-progression)

## Related deep dives

-   [GLP-1 drugs and brain health: what the evidence means for APOE4 The first big Alzheimer's trial of a GLP-1 drug just reported. The honest answer about your brain is more nuanced than the hype or the backlash.](/topics/glp-1-drugs-and-the-brain)
-   [Metabolic health, insulin resistance, and the APOE4 brain Blood sugar control is not only a diabetes issue. It is increasingly tied to brain health. What insulin resistance has to do with cognitive risk, the markers to watch, and what helps.](/topics/metabolic-health-insulin-resistance-apoe4)
-   [Reading a study like a skeptic: a carrier’s media-literacy guide APOE4 headlines swing from "cure" to "doom" weekly. A practical toolkit for reading health studies and news so you can tell real signal from hype, and act on the right things.](/topics/reading-a-study-like-a-skeptic)